Clinical Trial Update: A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of ramucirumab in pediatric patients with refractory solid tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Malignancies
• Solid Tumor
• Tumor

Drugs mentioned

• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Pediatric Solid Tumor, Refractory Tumor | Phase 1 | Status: COMPLETED | Results posted: 2021-08-17